Study #2024-0209
A phase 2/3, randomized, open-label, multicenter study to evaluate the safety and efficacy of FPI-2265 (225Ac-PSMA-I&T) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), previously treated with 177Lu-PSMA radioligand therapy (RLT)
MD Anderson Study Status
Enrolling
Treatment Agent
FPI-2265
Description
This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 in participants with PSMA-positive mCRPC who have been previously treated with 177Lu-PSMA-617 or another 177Lu-PSMA radioligand therapy (RLT).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Castration-resistant Prostate Cancer
Study phase:
Phase II/III
Physician name:
Amado Zurita-Saavedra
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-499-2252
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.